Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 229-240

  Walter, Sarah ^a   Baruch, Amos ^a   Dong, Jin ^a   Tomlinson, James E ^a   Alexander, Shawn T ^a   Janes, Julie ^a   Hunter, Tom ^a   Yin, Qun ^a   Maclean, Derek ^a   Bell, Gregory ^a,b   Mendel, Dirk B ^a   Johnson, Randolph M ^a   Karim, Felix ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 416; CALCIUM; CALCIUM SENSING RECEPTOR; CREATININE; FIBROBLAST GROWTH FACTOR 23 RECEPTOR; GROWTH FACTOR RECEPTOR; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VELCALCETIDE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; EMBRYO; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; MALE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ANIMALS; FEMALE; HEK293 CELLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY; MALE; NEPHRECTOMY; PARATHYROID GLANDS; PARATHYROID HORMONE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS; TISSUE DISTRIBUTION; UREMIA;

EID: 84880423881     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204834     Document Type: Article

References (38)

1. Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin D, and Ward DT, et al. (2009) Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 81:260-268.
2. Arnold A, Brown MF, Ureña P, Gaz RD, Sarfati E, and Drüeke TB (1995) Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95:2047-2053.
3. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, and Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, and Chertow GM (2004a) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218.
5. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, and Messa P,, et al. (2004b) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525.
6. Breitwieser GE and Gama L (2001) Calcium-sensing receptor activation induces intracellular calcium oscillations. Am J Physiol Cell Physiol 280:C1412-C1421.
7. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, and Hebert SC (1993) Cloning and characterization of an extracellular Ca(21)-sensing receptor from bovine parathyroid. Nature 366: 575-580.
8. Brown EM and MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239-297.
9. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, and Rodriguez M (2010) FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21: 1125-1135.
10. Chattopadhyay N, Mithal A, and Brown EM (1996) The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev 17:289-307.
11. Conigrave AD, Quinn SJ, and Brown EM (2000) Cooperative multi-modal sensing and therapeutic implications of the extracellular Ca(21) sensing receptor. Trends Pharmacol Sci 21:401-407.
12. Cunningham J, Locatelli F, and RodriguezM (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913-921.
13. Demer LL and Tintut Y (2008) Vascular calcification: pathobiology of a multifaceted disease. Circulation 117:2938-2948.
14. Drüeke TB (1995) The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 48:259-272.
15. Drüeke TB (2000) Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 11:1141-1152.
16. Drueke T, Martin D, and Rodriguez M (2007) Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 22: 1828-1839.
17. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, and Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443.
18. Galitzer H, Lavi-Moshayoff V, Nechama M, Meir T, Silver J, and Naveh-Many T (2009) The calcium-sensing receptor regulates parathyroid hormone gene expression in transfected HEK293 cells. BMC Biol 7:17.
19. Gincherman Y, Moloney K, McKee C, and Coyne DW (2010) Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int 14: 68-72.
20. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, and Drüeke TB (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328-336.
21. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, and Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215.
22. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, and Seidman CE (1995) A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 11:389-394.
23. Kifor O, Moore FD, Jr, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, and Brown EM (1996) Reduced immunostaining for the extracellular Ca21-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598-1606.
24. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, and Nakagawa K,, et al. (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232-238.
25. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, and Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131.
26. Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T, and Silver J (2006) Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 17:107-112.
27. Levine S and Saltzman A (1997) Carbohydrate diet prolongs survival of rats with acute uremia after bilateral nephrectomy. Nephron 77:242-243.
28. London GM, Marchais SJ, Guérin AP, and Métivier F (2005) Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 14:525-531.
29. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, and Rodriguez M (2006) Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17:795-804.
30. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, Henley C, Martin D, and Gattone VH, 2nd (2009) R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 24:2371-2377.
31. Mudò G, Trovato-Salinaro A, Barresi V, Belluardo N, and Condorelli DF (2009) Identification of calcium sensing receptor (CaSR) mRNA-expressing cells in normal and injured rat brain. Brain Res 1298:24-36.
32. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, KarbonW, Scherrer J, and Shatzen E, et al. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627-635.
33. Padhi D and Harris R (2009) Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 48:303-311.
34. Ritter CS, Finch JL, Slatopolsky EA, and Brown AJ (2001) Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60: 1737-1744.
35. Sheehan DC and Hrapchak BB (1980) Theory and Practice of Histotechnology, Mosby, St. Louis.
36. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, and Fukagawa M (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250-256.
37. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, and Hirakata H (2002) Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62:1196-1207.
38. Whittaker P, Kloner RA, Boughner DR, and Pickering JG (1994) Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89:397-410.